drugset / Trial / NCT05656105

Positron Emission Tomography (PET) Imaging of Neuroinflammation in Patients With Neurological Dysfunction After Severe Acute Respiratory Syndrome Coronavirus 2 (SARS CoV 2) Infection

NCT05656105 ↗

Phase 0 Recruiting 60 enrolled University of Alabama at Birmingham
Non-randomizedSingle-groupOpen-labelDiagnostic

Summary

This clinical imaging study will use the small molecule translocator protein (TSPO) ligand, Fluorodeoxyglucose(18F)-labeled DPA-714, to visualize and quantify neuroinflammation in individuals with post-acute sequelae of SARS-CoV-2 (PASC) . The brain uptake of DPA-714 will be contrasted with healthy subjects.

Timeline

Start
2023-11-10
Primary completion
2028-06-01
Completion
2028-06-01

Drugs

EvaluationDrugModalityDoseRoute
Subject DPA-714 Diagnostic / imaging agent — —

Indications